CYBN:CC News and Press, CYBIN INC. From 05/04/22

Depression is a mood disorder that causes an individual to experience feelings of sadness that persist for longer than a fortnight, which impacts their ability to carry out daily activities. A recently conducted study has found that individuals who use antidepressants to manage their depre...

New research has found that mushrooms have their own language that they use to talk to each other. The study, which was conducted by Professor Andrew Adamatzky of the University of the West of England, published its findings in the “Royal Society.” For their study, the rese...

Vancouver Island University has plans to expand its psychedelic-assisted therapy program by providing a graduate certificate program in the use of psychedelic drugs, such as psilocybin, in mental health care. This will make it the pioneer accredited university in Canada to do so. This ...

Cybin (NYSE American: CYBN) (NEO: CYBN) is a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions in a commitment to transform the mental health treatment landscape. Through its proprietary deuterated proc...

Patients with severe depression in the state of Colorado who haven’t been successful in managing their indication with antidepressants have turned to ketamine. Ketamine is a prescription drug used by veterinarians and medical practitioners as an anesthetic. Researchers at Yale have ...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 28, 2022 – Oregon is set to become the first US state to market legal psilocybin , the psychoactive substance found in magic mushrooms. Authorities plan to greenlight a par...

New research has discovered a link between changes in the function and shape of immune cells, mechanical changes in blood cells and persistent depressive disorders. Depressive disorders are one of the primary causes of disability around the globe. Depression is known to cause an increase i...

Currently, there are a number of ongoing and planned clinical trials looking into the use of psychedelic therapies in the treatment of post-traumatic stress disorder (PTSD). Most of these trials focus on one particular psychedelic , MDMA, which is commonly known as ecstasy. However, other...

Cybin (NYSE American: CYBN) (NEO: CYBN) , a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that its CEO Doug Drysdale will present at the KCSA Psychedelics Virtual Investor Conference . Drysdale’s presentation is slat...

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™” is pleased to announce that Doug Drysdale, Cybin’s Chie...